ArticleNature2026
A disease model resource reveals core principles of tissue-specific cancer evolution.
Abstract read
In one paragraph
Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Tutorial: interrogating biology using organoid technologies.Nature protocols · 2026Review
- Gene mutant dosage is associated with prognosis and metastatic tropism in 60,000 clinical cancer samples.Nature genetics · 2026Article
- SERPINI1 functions as a tumor suppressor in glioma.Scientific reports · 2026Article
- The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma.MedComm · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
66 authors.
Sebastian Mueller *Institute of Molecular Oncology and Functional Genomics, School of Medicine and Health, TU Munich, Munich, Germany.ORCID http://orcid.org/0009-0008-1514-3027
Niklas de Andrade Krätzig *Institute of Molecular Oncology and Functional Genomics, School of Medicine and Health, TU Munich, Munich, Germany.ORCID http://orcid.org/0000-0003-2141-6745
Markus Tschurtschenthaler *Institute for Translational Cancer Research (TranslaTUM), School of Medicine and Health, TU Munich, Munich, Germany.ORCID http://orcid.org/0000-0002-0060-4790
Miguel G SilvaInstitute of Molecular Oncology and Functional Genomics, School of Medicine and Health, TU Munich, Munich, Germany.
Chiara ThordsenInstitute of Molecular Oncology and Functional Genomics, School of Medicine and Health, TU Munich, Munich, Germany.
Riccardo TrozzoInstitute of Molecular Oncology and Functional Genomics, School of Medicine and Health, TU Munich, Munich, Germany.ORCID http://orcid.org/0000-0002-5889-994X
Perrine SimonInstitute of Molecular Oncology and Functional Genomics, School of Medicine and Health, TU Munich, Munich, Germany.
Frederic SaabInstitute for Translational Cancer Research (TranslaTUM), School of Medicine and Health, TU Munich, Munich, Germany.ORCID http://orcid.org/0000-0002-3351-8274
Thorsten KaltenbacherInstitute of Molecular Oncology and Functional Genomics, School of Medicine and Health, TU Munich, Munich, Germany.ORCID http://orcid.org/0000-0001-8233-4749
Magdalena ZukowskaInstitute for Translational Cancer Research (TranslaTUM), School of Medicine and Health, TU Munich, Munich, Germany.
Daniele LucarelliInstitute for Translational Cancer Research (TranslaTUM), School of Medicine and Health, TU Munich, Munich, Germany.ORCID http://orcid.org/0000-0002-0393-3848
Rupert ÖllingerInstitute of Molecular Oncology and Functional Genomics, School of Medicine and Health, TU Munich, Munich, Germany.ORCID http://orcid.org/0000-0002-2292-5982
Joscha GrigerInstitute of Molecular Oncology and Functional Genomics, School of Medicine and Health, TU Munich, Munich, Germany.ORCID http://orcid.org/0000-0001-8666-3371
Nina GroßInstitute of Molecular Oncology and Functional Genomics, School of Medicine and Health, TU Munich, Munich, Germany.
Tanja GrollComparative Experimental Pathology, School of Medicine and Health, TU Munich, Munich, Germany.ORCID http://orcid.org/0000-0002-9049-9145
Jessica LöprichInstitute of Molecular Oncology and Functional Genomics, School of Medicine and Health, TU Munich, Munich, Germany.
Antonio E ZauritoInstitute for Translational Cancer Research (TranslaTUM), School of Medicine and Health, TU Munich, Munich, Germany.
Linus R SchömigKlinik für Innere Medizin II, Universitätsklinikum Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0002-9434-0334
Jeroen M BugterInstitute of Molecular Oncology and Functional Genomics, School of Medicine and Health, TU Munich, Munich, Germany.ORCID http://orcid.org/0000-0001-9920-2937
Stefanie BärthelInstitute for Translational Cancer Research (TranslaTUM), School of Medicine and Health, TU Munich, Munich, Germany.ORCID http://orcid.org/0000-0001-5986-4864
Chiara FalcomatàInstitute for Translational Cancer Research (TranslaTUM), School of Medicine and Health, TU Munich, Munich, Germany.ORCID http://orcid.org/0000-0001-9269-2582
Alexander StrongGenome Campus, Wellcome Trust Sanger Institute, Hinxton, UK.
Cordelia BrandtGenome Campus, Wellcome Trust Sanger Institute, Hinxton, UK.
Mulham NajajrehCenter for Functional Protein Assemblies, TU Munich, Garching, Germany.ORCID http://orcid.org/0000-0002-3355-8866
Aristeidis PapargyriouCenter for Functional Protein Assemblies, TU Munich, Garching, Germany.ORCID http://orcid.org/0000-0002-2577-4737
Roman MareschInstitute of Molecular Oncology and Functional Genomics, School of Medicine and Health, TU Munich, Munich, Germany.ORCID http://orcid.org/0000-0003-3393-8882
Katharina A N CollinsInstitute of Molecular Oncology and Functional Genomics, School of Medicine and Health, TU Munich, Munich, Germany.
David SailerInstitute of Molecular Oncology and Functional Genomics, School of Medicine and Health, TU Munich, Munich, Germany.
Christian SchneeweisInstitute for Translational Cancer Research (TranslaTUM), School of Medicine and Health, TU Munich, Munich, Germany.
Sebastian BurgerInstitute of Molecular Oncology and Functional Genomics, School of Medicine and Health, TU Munich, Munich, Germany.ORCID http://orcid.org/0009-0005-1326-5686
Lisa M FröhlichGerman Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Christine KlementInstitute of Molecular Oncology and Functional Genomics, School of Medicine and Health, TU Munich, Munich, Germany.ORCID http://orcid.org/0000-0003-1446-3703
Alexander BelkaInstitute of Molecular Oncology and Functional Genomics, School of Medicine and Health, TU Munich, Munich, Germany.
Juan J MonteroInstitute of Molecular Oncology and Functional Genomics, School of Medicine and Health, TU Munich, Munich, Germany.
Ute JungwirthNewcastle Drug Discovery Group, Translational and Clinical Research Institute, Newcastle University, Newcastle, UK.ORCID http://orcid.org/0000-0002-4673-3096
Maximilian ReichertGerman Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Markus MoserInstitute of Experimental Hematology, School of Medicine and Health, TU Munich, Munich, Germany.ORCID http://orcid.org/0000-0001-8825-5566
Jens NeumannInstitute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany.
George VassiliouDepartment of Haematology, Cambridge University Hospitals NHS Trust, Cambridge, UK.ORCID http://orcid.org/0000-0003-4337-8022
Juan CadiñanosFundación Centro Médico de Asturias, Oviedo, Spain.ORCID http://orcid.org/0000-0001-7561-7759
Ignacio VarelaInstituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Universidad de Cantabria-CSIC, Santander, Spain.ORCID http://orcid.org/0000-0002-0969-506X
Carsten MarrGerman Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0003-2154-4552
Daniel F AlonsoCenter for Molecular and Translational Oncology (COMTra), National University of Quilmes (UNQ), Buenos Aires, Argentina.ORCID http://orcid.org/0000-0002-0601-613X
Pier-Luigi LolliniDepartment of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
Jean ZhaoBroad Institute of Harvard and MIT, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-4561-5688
Louis CheslerDivision of Clinical Studies, The Institute of Cancer Research (ICR) and Royal Marsden NHS Trust, Sutton, UK.ORCID http://orcid.org/0000-0001-7842-2068
Clare M IsackeBreast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-9222-3345
Angela RiedelMildred Scheel Early Career Centre, University Hospital of Würzburg, Würzburg, Germany.
Christian J BraunInstitute of Molecular Oncology and Functional Genomics, School of Medicine and Health, TU Munich, Munich, Germany.
Martin L SosGerman Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Filippo BeleggiaDepartment of Translational Genomics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID http://orcid.org/0000-0003-0234-7094
Hans C ReinhardtGerman Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0001-5706-9349
Monica MusteanuCentro de Investigación Biomédica en Red de Cáncer, Instituto de Salud Carlos III, Madrid, Spain.
Mariano BarbacidCentro de Investigación Biomédica en Red de Cáncer, Instituto de Salud Carlos III, Madrid, Spain.
Michael QuanteGerman Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Marc Schmidt-SupprianInstitute for Translational Cancer Research (TranslaTUM), School of Medicine and Health, TU Munich, Munich, Germany.ORCID http://orcid.org/0000-0002-8543-6166
Günter SchneiderInstitute for Translational Cancer Research (TranslaTUM), School of Medicine and Health, TU Munich, Munich, Germany.ORCID http://orcid.org/0000-0003-1840-4508
Simon ClareGenome Campus, Wellcome Trust Sanger Institute, Hinxton, UK.
Trevor D LawleyGenome Campus, Wellcome Trust Sanger Institute, Hinxton, UK.ORCID http://orcid.org/0000-0002-4805-621X
Gordon DouganGenome Campus, Wellcome Trust Sanger Institute, Hinxton, UK.
Katja SteigerGerman Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-7269-5433
Nathalie ConteGenome Campus, Wellcome Trust Sanger Institute, Hinxton, UK.
Allan BradleyGenome Campus, Wellcome Trust Sanger Institute, Hinxton, UK.
Lena RadInstitute for Translational Cancer Research (TranslaTUM), School of Medicine and Health, TU Munich, Munich, Germany.
Dieter SaurInstitute for Translational Cancer Research (TranslaTUM), School of Medicine and Health, TU Munich, Munich, Germany.ORCID http://orcid.org/0000-0001-5874-0210
Roland RadInstitute of Molecular Oncology and Functional Genomics, School of Medicine and Health, TU Munich, Munich, Germany. roland.rad@tum.de.ORCID http://orcid.org/0000-0002-6849-9659
Funding
Integrating targeted therapy and immunotherapy to break through cancerR35CA210057 · NCI · DANA-FARBER CANCER INST · PI Jean Zhao · 2016 to 2026
$10.8MNCI NIH HHS R35 CA210057
Abstract
Oncogenes such as KRAS display marked tissue specificity in their oncogenic potential, genetic interactions and phenotypic effects, but the underlying determinants remain largely unresolved
Indexed as
Evolution, MolecularNeoplasmsOrgan SpecificityAnimalsCarcinogenesisCell DifferentiationCell Line, TumorDisease Models, AnimalEpistasis, GeneticFemaleGene DosageGenes, Tumor SuppressorHumansMaleMiceMutationHras protein, mouseKRAS protein, humanProto-Oncogene Proteins p21(ras)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.